MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
批准号:
10327336
负责人:
David Gius
金额:
$36.08万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-01-09 至 2025-12-31
关键词:
AcetylationAdjuvant TherapyBiological MarkersBiologyBreastBreast Cancer CellCell physiologyCellsCellular Metabolic ProcessChIP-seqChemicalsCisplatinClustered Regularly Interspaced Short Palindromic RepeatsComplexDataDoxorubicinDrug Metabolic DetoxicationEndocrineEquilibriumEstrogen receptor positiveEventExhibitsExposure toFatty acid glycerol estersFulvestrantGenesGrantKnock-outLeadLinkLysineMCF7 cellMalignant NeoplasmsMammary NeoplasmsMeasurementMeasuresMediatingMetabolicMetabolismMitochondriaModelingNatureOncogenicPathway interactionsPeroxidasesPhenotypePhysiologicalPost-Translational Protein ProcessingPropertyPublicationsReactive Oxygen SpeciesRecurrenceReporterResistanceRiskSOD2 geneSelective Estrogen Receptor ModulatorsSignal TransductionSirtuinsStainsSubgroupSuperoxidesSystemic TherapyT47DTamoxifenTechniquesTestingTimeTissue MicroarrayTumor PromotersWomanWorkXenograft Modelbasebreast malignanciescancer cellhigh riskhormone therapyin vivoknock-downmammarymimeticsmitochondrial metabolismmouse modelmutantneoplastic cellnew therapeutic targetnovelpatient derived xenograft modelpreventpublic databaseresponsesmall hairpin RNAstemstem cell biomarkersstem-like cellstemnesstargeted treatmenttherapy resistanttissue culturetranscriptome sequencingtumortumorigenesistumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY
The dysregulation of mitochondrial networks responsible for maintaining normal metabolism is an
established hallmark of cancer and an early event in tumorigenesis. The disruption of cell metabolism
leads to accumulation of reactive oxygen species (ROS) and triggers maladaptive signaling that
disrupts metabolic balance, which can establish a tumorigenic and/or therapy resistant phenotype.
In this regard, a subgroup of estrogen receptor-positive (ER+) breast malignancies, which exhibit
increased ROS levels and a high risk of recurrence due to endocrine therapy, has been identified.
We recently found a novel mitochondrial signaling axis centered on manganese superoxide
dismutase (MnSOD), which when the acetylation (Ac) status of lysine 68 (K68-Ac) is altered, disrupts
cell metabolism, leading to aberrant ROS levels (Zhu, Nature Commun., 2019). In addition, breast
cancer cells expressing a MnSOD-K68-Ac mimic mutant (MnSODK68Q) exhibited increased HIF2α
(known to promote stemness-like properties), increased SOX2 and Oct4 (two established stem cell
biomarkers), leading to oncogenicity and pan resistance phenotype (PanR) to agents commonly
used in luminal B breast malignancies-implying that disruption of cell metabolism reprograms tumors
to exhibit a lineage plasticity phenotype. Based on our new data, our recent publication (Zhu et al,
Nature Commun. 2019), and work by others, it is hypothesized that dysregulated MnSOD biology,
due to aberrant/increased MnSOD-K68-Ac levels, disrupts normal cellular and mitochondrial
metabolism. This initiates metabolic reprogramming, via increased levels of HIF2α, leading to a cell
stemness-mediated tumor-permissive and/or PanR phenotype. Thus, we seek to further explore how
MnSOD-K68-Ac disrupts cell metabolism and promotes a stemness-like phenotype, leading to
oncogenicity and/or PanR. Finally, will GC4419 exposure, a chemical SOD detoxification mimic,
reverse the oncogenic and/or PanR phenotypes?
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
-
批准号:10737810
-
项目类别:
-
资助金额:$6.81万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
-
批准号:10533472
-
项目类别:
-
资助金额:$6.95万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
-
批准号:10390451
-
项目类别:
-
资助金额:$37.61万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies.
-
批准号:10817556
-
项目类别:
-
资助金额:$5.07万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
-
批准号:10335424
-
项目类别:
-
资助金额:$38.95万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
-
批准号:10541193
-
项目类别:
-
资助金额:$36.08万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
-
批准号:10548835
-
项目类别:
-
资助金额:$37.61万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
-
批准号:10024964
-
项目类别:
-
资助金额:$7.28万
-
财政年份:2017
-
负责人:David Gius
-
依托单位:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
-
批准号:9889066
-
项目类别:
-
资助金额:$39.02万
-
财政年份:2017
-
负责人:David Gius
-
依托单位:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
-
批准号:9262705
-
项目类别:
-
资助金额:$39.65万
-
财政年份:2017
-
负责人:David Gius
-
依托单位:
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers
-
批准号:8401029
-
项目类别:
-
资助金额:$37.96万
-
财政年份:2012
-
负责人:David Gius
-
依托单位:
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers
-
批准号:8549177
-
项目类别:
-
资助金额:$35.68万
-
财政年份:2012
-
负责人:David Gius
-
依托单位:
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers
-
批准号:8704896
-
项目类别:
-
资助金额:$36.82万
-
财政年份:2012
-
负责人:David Gius
-
依托单位:
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers
-
批准号:8890802
-
项目类别:
-
资助金额:$37.96万
-
财政年份:2012
-
负责人:David Gius
-
依托单位:
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers
-
批准号:9114533
-
项目类别:
-
资助金额:$37.96万
-
财政年份:2012
-
负责人:David Gius
-
依托单位:
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors
-
批准号:8547783
-
项目类别:
-
资助金额:$29.77万
-
财政年份:2011
-
负责人:David Gius
-
依托单位:
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors
-
批准号:8703629
-
项目类别:
-
资助金额:$30.67万
-
财政年份:2011
-
负责人:David Gius
-
依托单位:
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors
-
批准号:8050512
-
项目类别:
-
资助金额:$32.32万
-
财政年份:2011
-
负责人:David Gius
-
依托单位:
Loss of mtSIRT3, Decreased MnSOD Activity, and IR Induced Genomic Instability
-
批准号:8408793
-
项目类别:
-
资助金额:$36.77万
-
财政年份:2010
-
负责人:David Gius
-
依托单位:
Loss of Mitochondrial Sirt3, Decreased MnSOD Activity, and IR Induced Genomic Instability
-
批准号:8914122
-
项目类别:
-
资助金额:$36.27万
-
财政年份:2010
-
负责人:David Gius
-
依托单位:
海外基金